PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-184.01%
Negative net income growth while AGEN stands at 93.81%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-9.94%
Negative yoy D&A while AGEN is 92.88%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-368.86%
Negative yoy deferred tax while AGEN stands at 100.46%. Joel Greenblatt would consider near-term tax obligations but a possible advantage if competitor's deferrals become a burden later.
368.86%
SBC growth well above AGEN's 14.21%. Michael Burry would flag major dilution risk vs. competitor’s approach.
55.40%
Slight usage while AGEN is negative at -1743.78%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
252.95%
A yoy AP increase while AGEN is negative at -59.91%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
-12.95%
Both reduce yoy usage, with AGEN at -23.04%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
200.11%
Some yoy increase while AGEN is negative at -2275.30%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-85.28%
Both yoy CFO lines are negative, with AGEN at -82.61%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
80.16%
Some CapEx rise while AGEN is negative at -159.44%. John Neff would see competitor possibly building capacity while we hold back expansions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
80.16%
Lower net investing outflow yoy vs. AGEN's 613.91%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
54.75%
We repay more while AGEN is negative at -50.00%. John Neff notes advantage in lowering leverage if competitor is ramping up debt or repaying less.
-0.41%
Negative yoy issuance while AGEN is 1600.81%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.